Reconstructive Surgery Clinical Trial
Official title:
Prospective Follow-up Study for the Evaluation of the Safety and Efficacy of the Dermal Substitute NEVELIA® in the Treatment of Third-degree Burns and Reconstructive Surgery
The dermal substitute NEVELIA® has received CE marking in July 9, 2013. Its use in the NEVAL
protocol will be in accordance with its leaflet, i.e. for the treatment of burns or in case
of reconstructive plastic surgery.
The matric implantation will be followed by autologous skin grafting when the neodermis
formation will be observed.
The NEVAL protocol is a descriptive study conducted in order to confirm the clinical
evidence of safety and performance of NEVELIA®, as described in the literature on equivalent
products.
This dermal substitute consists of an inner biodegradable dermal substitute made of bovine
collagen (collagen of type I), covered with an outer silicone membrane. Its porosity and the
speed of degradation allow the act of recolonization by the fibroblasts and initiation of
the vascularization process within 3 weeks. The application procedure requires removement of
the silicone layer and wound covering with an ultra-thin epidermal graft, possibly meshed.
This surgical procedure is well-known and permits an ultra-thin epidermal graft.
All the patients will be treated with NEVELIA®, prior to autologous skin grafting within 3
weeks after its application. Then, three follow-up visits will be planned: post operatively,
at 6 and 12 months.
The objectives are:
- Primary objective: To assess the type and frequency of complications
- Secondary objectives:
- To assess the take rate of NEVELIA®
- To assess the take rate of skin graft
- To assess the satisfaction rate of physician and patient,
- To assess the quality of the healed skin,
- To assess the rate of re-operation at 12 months.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01204554 -
Microcirculation in Perforator Flaps. Enhancing Tissue Survival
|
Phase 0 | |
Completed |
NCT00872859 -
The BREASTrial:Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial
|
Phase 4 | |
Completed |
NCT05267197 -
3D Telemedicine: A Clinician Feedback Study
|
||
Completed |
NCT02411292 -
Enoxaparin Metabolism in Reconstructive Surgery Patients
|
Phase 2 | |
Completed |
NCT04002713 -
Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer
|
||
Completed |
NCT03212365 -
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
|
Phase 2 | |
Recruiting |
NCT05032768 -
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
|
||
Recruiting |
NCT04261829 -
AFT: Introduction of a Full Breast Reconstructive Method
|
||
Completed |
NCT04195854 -
STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use
|
||
Completed |
NCT06447610 -
Lateral Arm Free Flap: a Useful Flap in the Maxillo-facial Surgeon's Therapeutic Armory, Case Series
|
||
Recruiting |
NCT03899051 -
PRF and Connective Tissue Graft in Interdental Papilla Reconstruction
|
N/A | |
Terminated |
NCT01681797 -
Fluorescence Angiography: Planning and Monitoring of Perforator Flaps
|
N/A |